imeglimin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antihyperglycaemics | 5483 | 775351-65-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Imeglimin is a first-in-class oral agent which improves pancreatic beta-cell function and enhances insulin action in key tissues, including liver and skeletal muscle.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 23, 2021 | PMDA | SUMITOMO DAINIPPON PHARMA Co., Ltd. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BX15 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Other blood glucose lowering drugs, excl. insulins |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| UU226QGU97 | UNII |
| 2650481-44-8 | SECONDARY_CAS_RN |
| C3501765 | UMLSCUI |
| CHEMBL4297514 | ChEMBL_ID |
| 24812808 | PUBCHEM_CID |
| DB12509 | DRUGBANK_ID |
| 8969 | INN_ID |
| D11807 | KEGG_DRUG |
| C575881 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
None